Cowen Raises Price Target on Acadia Pharma (ACAD) Following 2Q15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
- Dara Khosrowshahi steps down from Grab Holdings board
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results
August 6, 2015 4:01 PM EDTSAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the second quarter ended June 30, 2015.
ACADIA reported a net loss of $39.4 million, or $0.39 per common share, for the second quarter of 2015 compared to a net loss of $21.5 million, or $0.22 per common share, for the second quarter of 2014. Net losses for the second quarters of 2015 and 2014 included $7.5 million and $4.3 million, respectively, in non-cash... More
ACADIA Pharmaceuticals Announces Publication of Data from Its -015 Open Label Safety Study in Parkinson’s Disease Psychosis in the Journal of the American Medical Directors Association
August 6, 2015 9:00 AM EDTSAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced the publication of new data from its ongoing open-label safety extension study, the -015 Study, with NUPLAZID in patients with Parkinsons disease psychosis (PDP) in the July 31 online issue of the Journal of the American Medical Directors Association... More
ACADIA Pharmaceuticals Announces Senior Management Appointments in Manufacturing, Quality, Compliance, Access and Reimbursement and Business Development
August 5, 2015 9:00 AM EDTSAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced the following senior management appointments:
James A. Nash, Senior Vice President, Technology Development and Operations Ryan E. Brown, Vice President, Chief Compliance Officer Fred W. Manak, Jr., Vice President, Access and Reimbursement Bob Mischler, Vice President, Strategy and Business Development... More